• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Cardiology

Beta-blockers do not lower mortality after myocardial infarction with preserved ejection fraction

byNhat Hung (Benjamin) LamandKiera Liblik
April 24, 2024
in Cardiology, Chronic Disease
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

1. In this randomized controlled trial, long-term beta-blockers did not impact all-cause mortality among patients with preserved left ventricular ejection fraction (LVEF) following an acute myocardial infarction (MI) and early angiography. 

2. Long-term beta-blocker therapy was not associated with a higher risk of adverse events compared to no beta-blocker.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Beta-blockers are a mainstay therapy for heart failure with reduced LVEF. Although historical evidence generally suggested the mortality benefits of beta-blockers following an MI, this predated the diagnostic and therapeutic advancements available today. Furthermore, evidence for beta-blocker therapy specifically for patients with preserved LVEF following acute MIs, especially with early revascularization, is lacking. This trial investigated the effects of long-term beta-blocker therapy against no beta-blocker in patients with an acute MI following coronary angiography who had LVEF ≥50%. At 3.5 years median follow-up, beta-blocker treatment was shown to not impact the risks of death from any cause, new MI, or hospitalization for atrial fibrillation or heart failure, compared to no beta-blocker. Beta-blocker therapy was also not associated with an increased risk of adverse events, including hospitalizations for bradycardia, stroke, or asthma. The study was limited by a lack of blinding and potential for crossover intrinsic to its open-label, pragmatic design. Nevertheless, these findings provided generalizable evidence that beta-blockers did not reduce the composite risk of all-cause mortality or new MI among patients with preserved ejection fraction following an acute MI.

Click here to read the study in the NEJM (New England Journal of Medicine)

In-Depth [randomized controlled trial]: This was a randomized, open-label, pragmatic trial to evaluate the impact of long-term beta-blocker therapy initiated early in patients with preserved LVEF. Adult patients were eligible for inclusion at one to seven days after an acute MI if they had undergone coronary angiography demonstrating obstructive coronary disease and had a preserved LVEF (≥50%) demonstrated on echocardiogram. Exclusion criteria included any indication for or contraindication to beta-blocker therapy. From 2017 to 2023, 5020 patients were enrolled and randomized 1:1 to start beta-blocker therapy (either metoprolol targeting 100mg daily or bisoprolol targeting 5mg daily) during their hospitalization or receive no beta-blockers. Patients in the no-beta-blocker group were discouraged from using beta-blockers if there were no other indications than secondary MI prevention. The primary outcome was a composite of death from any cause and a new MI. With the median follow-up of 3.5 years, the composite primary outcome occurred in 7.9% of the beta-blocker group and 8.3% of the no-beta-blocker group (hazard ratio [HR], 0.96; 95% Confidence Interval [CI], 0.79 to 1.16; p=0.64). Correspondingly, the rates of secondary outcomes were similar between the beta-blocker and the no-beta-blocker groups, respectively: death from any cause (3.9% vs. 4.1%; HR, 0.94; 95% CI, 0.71 to 1.24), death from cardiovascular causes (1.5% vs. 1.3%; HR, 1.15; 95% CI, 0.72-1.84), MI (4.5% vs. 4.7%; HR, 0.96; 95% CI, 0.74 to 1.24), hospitalization for atrial fibrillation (1.1% vs. 1.4%; HR, 0.79; 95% CI, 0.48 to 1.31), and hospitalization for heart failure (0.5% vs. 0.9%; HR, 0.91; 95% CI, 0.50 to 1.66). Overall, among patients who had a preserved LVEF following an acute MI, beta-blockers did not impact the composite risk of death from any cause or new MI.

RELATED REPORTS

Spousal traumatic brain injury is associated with increased mortality in the uninjured partner

2 Minute Medicine Rewind November 9, 2026

Image: PD

©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: beta blockercardiologychronic diseasemortalitymyocardial infarctionpreserved ejection fraction
Previous Post

#VisualAbstract: Sentinel-node biopsy only is noninferior to completion of axillary lymph node dissection in breast cancer with sentinel-node metastases

Next Post

High dose aflibercept may be promising for treatment of age-related macular degeneration

RelatedReports

Collage on head injury in adults: a calm man beside an engraved brain drawing, a bicycle helmet and a small penlight
Chronic Disease

Spousal traumatic brain injury is associated with increased mortality in the uninjured partner

November 13, 2026
A profile of a human head with a visible brain, surrounded by descending bar graphs and doors leading into a fading background, suggesting themes of dementia and cognitive decline.
Weekly Rewinds

2 Minute Medicine Rewind November 9, 2026

November 11, 2026
A pregnant woman consults with a healthcare provider, who is holding a clipboard and discussing maternal health topics. A weight scale and imagery of a fetus are also present.
Cardiology

Medicaid status, race and ethnicity are independently associated with increased odds of severe maternal morbidity

November 6, 2026
IV line infection collage: a winged IV catheter, a clear dressing, three blue circles along a ribbon and round bacteria
Cardiology

Midline catheters may reduce catheter-related bloodstream infections compared with peripherally inserted central catheters in intensive care unit patients

November 5, 2026
Next Post
Blindness and visual impairment decreasing worldwide

High dose aflibercept may be promising for treatment of age-related macular degeneration

#VisualAbstract: Microaxial Flow Pumps Reduces Mortality But Increases Adverse Events Compared to Standard Care For Cardiogenic Shock

#VisualAbstract: Microaxial Flow Pumps Reduces Mortality But Increases Adverse Events Compared to Standard Care For Cardiogenic Shock

#VisualAbstract: Empagliflozin does not significantly reduce the risk of heart failure or death in patients after acute myocardial infarction

#VisualAbstract: Empagliflozin does not significantly reduce the risk of heart failure or death in patients after acute myocardial infarction

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Investigational retatrutide reduced knee osteoarthritis pain and body weight versus placebo in adults with obesity
  • FDA accepted an application to review at-home use of dexmedetomidine for agitation in schizophrenia and bipolar disorder
  • In a randomized sham-controlled trial, acupoint thread embedding produced a between-group difference in change from baseline of 1.8 kg at 12 weeks and 3.0 kg at 24 weeks in Chinese women with overweight or obesity
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.